IL309179A - Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses - Google Patents

Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses

Info

Publication number
IL309179A
IL309179A IL309179A IL30917923A IL309179A IL 309179 A IL309179 A IL 309179A IL 309179 A IL309179 A IL 309179A IL 30917923 A IL30917923 A IL 30917923A IL 309179 A IL309179 A IL 309179A
Authority
IL
Israel
Prior art keywords
klk2
nucleic acid
fusion protein
recombinant cells
acid coding
Prior art date
Application number
IL309179A
Other languages
English (en)
Hebrew (he)
Inventor
Stuart L Emanuel
Thomas J Rutkoski
Original Assignee
Janssen Biotech Inc
Stuart L Emanuel
Thomas J Rutkoski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Stuart L Emanuel, Thomas J Rutkoski filed Critical Janssen Biotech Inc
Publication of IL309179A publication Critical patent/IL309179A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6445Kallikreins (3.4.21.34; 3.4.21.35)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21035Tissue kallikrein (3.4.21.35)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/90Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL309179A 2021-06-10 2022-06-08 Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses IL309179A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (1)

Publication Number Publication Date
IL309179A true IL309179A (en) 2024-02-01

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309179A IL309179A (en) 2021-06-10 2022-06-08 Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses

Country Status (11)

Country Link
US (1) US20220403397A1 (enExample)
EP (1) EP4352217A1 (enExample)
JP (1) JP2024520790A (enExample)
KR (1) KR20240021211A (enExample)
CN (1) CN117480253A (enExample)
AU (1) AU2022291273A1 (enExample)
BR (1) BR112023025616A2 (enExample)
CA (1) CA3222756A1 (enExample)
IL (1) IL309179A (enExample)
MX (1) MX2023014793A (enExample)
WO (1) WO2022259190A1 (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6113917A (en) * 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
DK1716233T3 (da) * 2004-01-30 2009-10-26 Maxygen Holdings Ltd Reguleret stopkodongennemlæsning
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES
WO2012068317A2 (en) * 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
JP7235436B2 (ja) * 2014-11-10 2023-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 細胞の表面上にポリペプチドを発現させるための組成物および方法
AU2020322221A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
EP4352217A1 (en) 2024-04-17
CN117480253A (zh) 2024-01-30
MX2023014793A (es) 2024-03-25
US20220403397A1 (en) 2022-12-22
AU2022291273A1 (en) 2024-01-25
KR20240021211A (ko) 2024-02-16
BR112023025616A2 (pt) 2024-02-27
WO2022259190A1 (en) 2022-12-15
CA3222756A1 (en) 2022-12-15
JP2024520790A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
SG11202006431WA (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
WO2004099370A3 (en) NOVEL BACILLUS mHKcel CELLULASE
WO2014118360A3 (en) Carbohydrate degrading polypeptide and uses thereof
BR112022006842A2 (pt) Construtos de igf2 variante
WO2016130628A8 (en) Griffithsin mutants
WO2019084362A3 (en) Fusion protein and nucleic acid molecule for exogenous stimulant-dependent stress granule assembly
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
GB2614158B (en) Nucleic acid constructs for expressing polypeptides in cells
EP3976104A4 (en) ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS AND THEIR USES
SG11202009503PA (en) Engineered cells with modified host cell protein profiles
HK1250992A1 (zh) 表皮生长因子受体变体iii-间皮素融合物及其使用方法
IL309179A (en) Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses
HK40109642A (en) Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof
WO2013070796A3 (en) Propeptide-luciferase fusion proteins and methods of use thereof
IL319272A (en) ROVEL FUSION protein specific for CD137 and CD228
ZA201105921B (en) Fusion proteins,preparation process thereof and their use in recombinant protein expression systems
GB202209517D0 (en) Modified fusion proteins and nucleic acid constructs
ZA202110190B (en) Protein tapyl1, coding gene and use thereof
GB202307936D0 (en) Fusion protein